NASDAQ:ATYR • US0021202025
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ATYR PHARMA INC (ATYR).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-11-07 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-09-16 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2025-09-16 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2025-09-15 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-08-22 | Jefferies | Maintains | Buy -> Buy |
| 2025-06-20 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-06-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-18 | Leerink Partners | Initiate | Outperform |
| 2025-01-06 | Cantor Fitzgerald | Initiate | Overweight |
| 2024-12-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-29 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-04 | Wells Fargo | Initiate | Overweight |
| 2024-09-05 | Jefferies | Initiate | Buy |
| 2024-08-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-14 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-08-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 353K -96.60% | 235K -33.43% | 190K -19.15% | 18.485M 9,628.95% | 47.495M 156.94% | 74.197M 56.22% | 190.28M 156.45% | 356.33M 87.27% | 559.52M 57.02% | 722.67M 29.16% | 902.48M 24.88% | |
| EBITDA YoY % growth | -54.327M -17.66% | -67.206M -23.71% | -76.963M -14.52% | -21.42M 72.17% | -3.706M 82.70% | -118.116M -3,087.16% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -54.919M -18.35% | -67.914M -23.66% | -77.627M -14.30% | -79.694M -2.66% | -48.072M 39.68% | -56.105M -16.71% | 55.696M 199.27% | 210.29M 277.57% | 363.39M 72.80% | 500.34M 37.69% | 657.94M 31.50% | |
| Operating Margin | -15,557.79% | -28,899.57% | -40,856.32% | -431.13% | -101.22% | -75.62% | 29.27% | 59.02% | 64.95% | 69.23% | 72.90% | |
| EPS YoY % growth | -0.96 40.00% | -0.87 9.37% | -0.79 9.20% | -0.60 24.63% | -0.49 17.56% | -0.14 71.26% | 0.62 542.88% | 1.36 117.55% | 3.13 130.39% | 4.15 32.41% | 5.28 27.43% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.14 18.57% | -0.17 24.27% | -0.16 39.85% | -0.05 67.21% |
| Revenue Q2Q % growth | 2.55M 1,242.11% | 9.935M | ||
| EBITDA Q2Q % growth | -15.3M 1.96% | -19.992M -0.06% | -21.42M 18.39% | N/A |
| EBIT Q2Q % growth | -14.042M 10.97% | -18.069M 11.05% | -17.061M 36.21% | -11.419M 22.82% |
All data in USD
17 analysts have analysed ATYR and the average price target is 6.48 USD. This implies a price increase of 628.32% is expected in the next year compared to the current price of 0.8903.
ATYR PHARMA INC (ATYR) will report earnings on 2026-05-05.
The consensus EPS estimate for the next earnings of ATYR PHARMA INC (ATYR) is -0.14 USD and the consensus revenue estimate is 0 USD.
The expected long term growth rate for ATYR PHARMA INC (ATYR) is 810.88%.